The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy

Enrica Riva, Filippo Salvini, Maria L. Garlaschi, Giovanni Radaelli, Marcello Giovannini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Streptococcus pneumoniae is a leading cause of invasive infection in young children causing morbidity and mortality. Active surveillance systems of invasive pneumococcal disease (IPD) are recommended worldwide. The aim of this study was to estimate the current incidence of IPD and to describe the serotype distribution and the antimocrobial susceptibility of S. pneumoniae isolates in children aged less than 5 years residing in North-West Lombardy, Italy.Methods: A twelve-month prospective active surveillance system recruited all children aged less than 5 years admitted for suspicion of IPD at emergency room of ten hospitals located in the monitored area. Blood samples were taken in all participants for confirmation of IPD based on isolation of S. pneumoniae from blood. Pneumococcal meningitis and sepsis were additionally confirmed by cerebrospinal fluid analysis. Serotyping and antimicrobial susceptibility testing were performed on isolates from blood.Results: A total of 15 confirmed cases of IPD were detected among 135 recruited children, including pneumonia (n = 8), bacteremia (n = 4), sepsis (n = 2) and meningitis (n = 1). The annual IPD incidence rate was 50.0/100,000 (95%CI, 30.5-82.5/100,000). Incidence was 58.3/100,000 (28.8-120.1/100,000) among children aged less than 2 years and 44.4/100,000 (22.9-87.5/100,000) among children aged 2-4 years. Thirteen isolates were typified. The most common serotype was 19A (23.1%) that together with serotypes 1, 7F and 19F accounted for 69.2% of typified isolates. Serotypes 14, 23F, 12B and 15C were also identified. The 7- and 13-valent pneumococcal conjugate vaccines covered respectively 30.8% and 84.6% of typified IPD cases. One isolate (serotype 15C) was penicillin-resistant and caused meningitis.Conclusions: The inclusion of the 13-valent pneumococcal conjugate vaccine in immunization programs of young children might be considered to reduce incidence and morbidity of invasive pneumococcal disease in this surveilled population.

Original languageEnglish
Article number106
JournalBMC Infectious Diseases
Volume12
DOIs
Publication statusPublished - May 3 2012

Fingerprint

Italy
Streptococcus pneumoniae
Conjugate Vaccines
Incidence
Meningitis
Sepsis
Pneumococcal Meningitis
Morbidity
Serotyping
Immunization Programs
Bacteremia
Penicillins
Cerebrospinal Fluid
Hospital Emergency Service
Pneumonia
Serogroup
Mortality
Infection
Population

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy. / Riva, Enrica; Salvini, Filippo; Garlaschi, Maria L.; Radaelli, Giovanni; Giovannini, Marcello.

In: BMC Infectious Diseases, Vol. 12, 106, 03.05.2012.

Research output: Contribution to journalArticle

Riva, Enrica ; Salvini, Filippo ; Garlaschi, Maria L. ; Radaelli, Giovanni ; Giovannini, Marcello. / The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy. In: BMC Infectious Diseases. 2012 ; Vol. 12.
@article{5d5a990b81b442238e47e4f3580fd5e3,
title = "The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy",
abstract = "Background: Streptococcus pneumoniae is a leading cause of invasive infection in young children causing morbidity and mortality. Active surveillance systems of invasive pneumococcal disease (IPD) are recommended worldwide. The aim of this study was to estimate the current incidence of IPD and to describe the serotype distribution and the antimocrobial susceptibility of S. pneumoniae isolates in children aged less than 5 years residing in North-West Lombardy, Italy.Methods: A twelve-month prospective active surveillance system recruited all children aged less than 5 years admitted for suspicion of IPD at emergency room of ten hospitals located in the monitored area. Blood samples were taken in all participants for confirmation of IPD based on isolation of S. pneumoniae from blood. Pneumococcal meningitis and sepsis were additionally confirmed by cerebrospinal fluid analysis. Serotyping and antimicrobial susceptibility testing were performed on isolates from blood.Results: A total of 15 confirmed cases of IPD were detected among 135 recruited children, including pneumonia (n = 8), bacteremia (n = 4), sepsis (n = 2) and meningitis (n = 1). The annual IPD incidence rate was 50.0/100,000 (95{\%}CI, 30.5-82.5/100,000). Incidence was 58.3/100,000 (28.8-120.1/100,000) among children aged less than 2 years and 44.4/100,000 (22.9-87.5/100,000) among children aged 2-4 years. Thirteen isolates were typified. The most common serotype was 19A (23.1{\%}) that together with serotypes 1, 7F and 19F accounted for 69.2{\%} of typified isolates. Serotypes 14, 23F, 12B and 15C were also identified. The 7- and 13-valent pneumococcal conjugate vaccines covered respectively 30.8{\%} and 84.6{\%} of typified IPD cases. One isolate (serotype 15C) was penicillin-resistant and caused meningitis.Conclusions: The inclusion of the 13-valent pneumococcal conjugate vaccine in immunization programs of young children might be considered to reduce incidence and morbidity of invasive pneumococcal disease in this surveilled population.",
author = "Enrica Riva and Filippo Salvini and Garlaschi, {Maria L.} and Giovanni Radaelli and Marcello Giovannini",
year = "2012",
month = "5",
day = "3",
doi = "10.1186/1471-2334-12-106",
language = "English",
volume = "12",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy

AU - Riva, Enrica

AU - Salvini, Filippo

AU - Garlaschi, Maria L.

AU - Radaelli, Giovanni

AU - Giovannini, Marcello

PY - 2012/5/3

Y1 - 2012/5/3

N2 - Background: Streptococcus pneumoniae is a leading cause of invasive infection in young children causing morbidity and mortality. Active surveillance systems of invasive pneumococcal disease (IPD) are recommended worldwide. The aim of this study was to estimate the current incidence of IPD and to describe the serotype distribution and the antimocrobial susceptibility of S. pneumoniae isolates in children aged less than 5 years residing in North-West Lombardy, Italy.Methods: A twelve-month prospective active surveillance system recruited all children aged less than 5 years admitted for suspicion of IPD at emergency room of ten hospitals located in the monitored area. Blood samples were taken in all participants for confirmation of IPD based on isolation of S. pneumoniae from blood. Pneumococcal meningitis and sepsis were additionally confirmed by cerebrospinal fluid analysis. Serotyping and antimicrobial susceptibility testing were performed on isolates from blood.Results: A total of 15 confirmed cases of IPD were detected among 135 recruited children, including pneumonia (n = 8), bacteremia (n = 4), sepsis (n = 2) and meningitis (n = 1). The annual IPD incidence rate was 50.0/100,000 (95%CI, 30.5-82.5/100,000). Incidence was 58.3/100,000 (28.8-120.1/100,000) among children aged less than 2 years and 44.4/100,000 (22.9-87.5/100,000) among children aged 2-4 years. Thirteen isolates were typified. The most common serotype was 19A (23.1%) that together with serotypes 1, 7F and 19F accounted for 69.2% of typified isolates. Serotypes 14, 23F, 12B and 15C were also identified. The 7- and 13-valent pneumococcal conjugate vaccines covered respectively 30.8% and 84.6% of typified IPD cases. One isolate (serotype 15C) was penicillin-resistant and caused meningitis.Conclusions: The inclusion of the 13-valent pneumococcal conjugate vaccine in immunization programs of young children might be considered to reduce incidence and morbidity of invasive pneumococcal disease in this surveilled population.

AB - Background: Streptococcus pneumoniae is a leading cause of invasive infection in young children causing morbidity and mortality. Active surveillance systems of invasive pneumococcal disease (IPD) are recommended worldwide. The aim of this study was to estimate the current incidence of IPD and to describe the serotype distribution and the antimocrobial susceptibility of S. pneumoniae isolates in children aged less than 5 years residing in North-West Lombardy, Italy.Methods: A twelve-month prospective active surveillance system recruited all children aged less than 5 years admitted for suspicion of IPD at emergency room of ten hospitals located in the monitored area. Blood samples were taken in all participants for confirmation of IPD based on isolation of S. pneumoniae from blood. Pneumococcal meningitis and sepsis were additionally confirmed by cerebrospinal fluid analysis. Serotyping and antimicrobial susceptibility testing were performed on isolates from blood.Results: A total of 15 confirmed cases of IPD were detected among 135 recruited children, including pneumonia (n = 8), bacteremia (n = 4), sepsis (n = 2) and meningitis (n = 1). The annual IPD incidence rate was 50.0/100,000 (95%CI, 30.5-82.5/100,000). Incidence was 58.3/100,000 (28.8-120.1/100,000) among children aged less than 2 years and 44.4/100,000 (22.9-87.5/100,000) among children aged 2-4 years. Thirteen isolates were typified. The most common serotype was 19A (23.1%) that together with serotypes 1, 7F and 19F accounted for 69.2% of typified isolates. Serotypes 14, 23F, 12B and 15C were also identified. The 7- and 13-valent pneumococcal conjugate vaccines covered respectively 30.8% and 84.6% of typified IPD cases. One isolate (serotype 15C) was penicillin-resistant and caused meningitis.Conclusions: The inclusion of the 13-valent pneumococcal conjugate vaccine in immunization programs of young children might be considered to reduce incidence and morbidity of invasive pneumococcal disease in this surveilled population.

UR - http://www.scopus.com/inward/record.url?scp=84860379054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860379054&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-12-106

DO - 10.1186/1471-2334-12-106

M3 - Article

VL - 12

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 106

ER -